摘要
弥漫大B细胞淋巴瘤(DLBCL)在形态学、免疫表型、分子病理、临床表型及预后都有明显异质性。基因组及转录组测序技术的发展,将DLBCL分为EZB、BN2、MCD、N1四个亚型或C1~C5五个亚型。新的分子病理分型从基因和分子层面对DLBCL进行了更深入的认识,使预后的判断更为准确,有利于临床筛选更精准的靶向治疗。
Diffuse large B-cell lymphoma(DLBCL)is characterized by heterogeneity with respect to morphology,immune phenotype,molecular pathogenesis,clinical presentation and prognosis.With the development of genome and transcriptome sequencing,DLBCL was classified as four subtypes(EZB,BN2,MCD,and N1)or five subtypes(C1-C5).The new molecular pathological typing has a deeper understanding of DLBCL from the levels of genes and molecules which makes the judgment of prognosis more accurate and specific,and it is conducive to the clinical screening of more accurate targeted therapy.
作者
侯强
史玉叶
桑威
王春玲
Hou Qiang;Shi Yuye;Sang Wei;Wang Chunling(Department of Hematology,the Huai'an Clinical College of Xuzhou Medical University,Huai'an 223300,China;Department of Hematology,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,China)
出处
《白血病．淋巴瘤》
CAS
2021年第2期125-128,共4页
Journal of Leukemia & Lymphoma
基金
江苏省卫生健康委员会项目(H2018085、H2019082)
淮安市科技计划(HAB201810)。
关键词
淋巴瘤
大B细胞
弥漫性
病理学
分子
分子分型
Lymphoma,large B-cell,diffuse
Pathology,molecular
Molecular typing
